Premium
Cisplatin Loaded Methoxy Poly (ethylene glycol)‐ block ‐Poly ( L ‐glutamic acid‐ co ‐ L ‐Phenylalanine) Nanoparticles against Human Breast Cancer Cell
Author(s) -
Ahmad Zaheer,
Tang Zhaohui,
Shah Afzal,
Lv Shixian,
Zhang Dawei,
Zhang Ying,
Chen Xuesi
Publication year - 2014
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201400109
Subject(s) - ethylene glycol , chemistry , nanocarriers , in vivo , cisplatin , nanoparticle , pharmacology , paclitaxel , nuclear chemistry , biophysics , drug delivery , cancer , nanotechnology , materials science , organic chemistry , medicine , chemotherapy , microbiology and biotechnology , surgery , biology
Cisplatin ( cis ‐diaminodichloroplatinum, CDDP) loaded methoxy poly (ethylene glycol)‐ block ‐poly (glutamic acid‐ co ‐phenyl alanine) [mPEG‐ b ‐P (Glu 10 ‐ co ‐Phe 10 ) (PGlu 10 ) and mPEG‐ b ‐P (Glu 20 ‐ co ‐Phe 10 ) (PGlu 20 )] nanoparticles with two different formulations (CDDP/PGlu 10 and CDDP/PGlu 20 ) are successfully developed in uniformly sizes. In 190 h, the CDDP/PGlu 10 shows 30% release at physiological pH and 39% at lysosomal pH. Similarly, the CDDP/PGlu 20 shows 60% release at physiological pH and 90% release at lysosomal pH. The sustained and controlled release of both formulations evidences the in vitro longevity of the nanoparticles. The cell proliferation inhibition of nanoparticles against human breast cancer cell line ZR‐75‐30 is dose and time dependent. Both CDDP/PGlu 10 and CDDP/PGlu 20 show excellent hemo compatibility as evaluated by hemolysis experiments. The in vivo fate of CDDP and CDDP loaded nanoparticles are evaluated by pharmacokinetics studies. Free CDDP underwgoes instant platinum concentration decrease after intravenous administration with 1.0 wt% left in 24 h while the CDDP loaded nanoparticles show prolonged blood circulation time with 5 wt% (CDDP/PGlu 20 ) to 14 wt% (CDDP/PGlu 10 ) left in 24 h. This prolonged blood circulation of CDDP loaded nanoparticles makes them as promising nanocarriers for tumor targeting delivery.